Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Genentech and Arvinas will work together to develop small molecules that invoke protein degradation and disposal. The pact, which includes an undisclosed up-front payment, could be worth up to $300 million in milestones for privately held Arvinas, which was spun out of the labs of Yale University chemist Craig Crews. Whereas conventional drugs work by blocking the activity of a protein, Arvinas is using bifunctional small molecules called proteolysis-targeting chimeras to “tag” certain proteins for breakdown by the ubiquitin-proteasome system.
This article has been sent to the following recipient: